New Hope in Finding the Magic Bullet

For this paper, Jim Kling interviewed David Lynch, senior staff scientist at Immunex Corp. in Seattle, Wash. Data from the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C.L. Schuh, D.H.T. Lynch, "Tumoricidal activity of tumor necrosis factor

Jim Kling
Jun 24, 2001
For this paper, Jim Kling interviewed David Lynch, senior staff scientist at Immunex Corp. in Seattle, Wash. Data from the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age.

H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C.L. Schuh, D.H.T. Lynch, "Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo," Nature Medicine, 5:157-63, February 1999. (Cited in 161 papers)


Soon after tumor necrosis factor (TNF) was discovered in 1985,1 the gene encoding this molecule was cloned.2 TNF generated much excitement because, as its name implies, TNF is deadly to tumor cells. Indeed, the hopes of many were raised that a powerful new cancer therapeutic had been...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?